Drug Trial Radar · NCT04456998
GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)
Last checked: Nov 20, 2026Latest source record: Nov 7, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
86
Actual
Start
Nov 12, 2020
Primary completion
Oct 17, 2022
Study completion Nov 1, 2022
Sponsor
- Lead sponsor
- GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 7, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective for this trial is to determine the effect of GB002 (seralutinib) on improving pulmonary hemodynamics in subjects with World Health Organization (WHO) Group 1 PAH who are Functional Class (FC) II and III. The secondary objective for this trial is to determine the effect of GB002 (seralutinib) on improving exercise capacity in this population.
Conditions
- Pulmonary Artery Hypertension
Interventions
GB002 (seralutinib)Drug
Capsule containing GB002 (seralutinib)
PlaceboDrug
Matching capsule containing placebo
Generic Dry Powder InhalerDevice
Generic dry powder inhaler for GB002 (seralutinib) or placebo delivery
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to Week 24 in Pulmonary Vascular Resistance (PVR)Time frame: Baseline, Week 24
Locations
63 sites in 11 countries. Site status is shown where the registry gives one.
Pulmonary Associates, PA
Phoenix, Arizona
Dept of Veterans Affairs Greater Los Angeles Healthcare System
Los Angeles, California
UC Davis Medical Center
Sacramento, California
The University of California San Francisco
San Francisco, California
Medical Corporation
Santa Barbara, California
Stanford Healthcare
Stanford, California
The Lundquist Institute of Biomedical Innovation at Harbor-UCLA Medical Center
Torrance, California
Central Florida Pulmonary Group, PA
Altamonte Springs, Florida
Mayo Clinic Jacksonville
Jacksonville, Florida
Cleveland Clinic Florida
Weston, Florida
The Emory Clinic
Atlanta, Georgia
University of Iowa Hospitals & Clinics
Iowa City, Iowa
University of Kansas Medical Center
Kansas City, Kansas
Kentuckiana Pulmonary Research Center
Louisville, Kentucky
Tufts Medical Center
Boston, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts
University of Michigan
Ann Arbor, Michigan
University of Minnesota
Minneapolis, Minnesota
Mayo Clinic
Rochester, Minnesota
Washington University School of Medicine
St Louis, Missouri
University of Nebraska Medical Center
Omaha, Nebraska
University of New Mexico Health Sciences Center
Albuquerque, New Mexico
NYU Langone Health
New York, New York
New York Presbyterian Hospital - Weill Cornell Medicine
New York, New York
University of Rochester Medical Center
Rochester, New York
University of Cincinnati Medical Center
Cincinnati, Ohio
Cleveland Clinic Foundation
Cleveland, Ohio
The Ohio State University Wexner Medical Center
Columbus, Ohio
INTEGRIS Baptist Medical Center, Inc.
Oklahoma City, Oklahoma
Oregon Health & Science University
Portland, Oregon
Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania
Allegheny General Hospital
Pittsburgh, Pennsylvania
UT Southwestern Medical Center
Dallas, Texas
Houston Methodist Hospital
Houston, Texas
University of Utah Health
Salt Lake City, Utah
Medical College of Wisconsin - Froedtert Hospital
Milwaukee, Wisconsin
St Vincent's Hospital Melbourne
Fitzroy, Australia
Royal Hobart Hospital
Hobart, Australia
Westmead Hospital
Westmead, Australia
St Vincent's Hospital
Darlinghurst, New South Wales, Australia
Showing 40 of 63 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.